Christos Fountzilas is an Oncology physician affiliated with Roswell Park Comprehensive Cancer Center. OpenAlex indexes 282 publications with 5,488 citations (h-index 24); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Elm And Carlton Streets
Buffalo, NY 142630001
Telephone
716-845-2300Registry record last updated 15 Jul 2019.
Clinical trials
- Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: Roswell Park Cancer Institute
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Sponsor: Roswell Park Cancer Institute
- FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
Sponsor: Roswell Park Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sirtex Medical IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Novel synthetic lethality strategy for TP53 mutant colorectal cancer
Roswell Park Cancer Institute Corp
FY2026$510,841R37CA282430 - Novel synthetic lethality strategy for TP53 mutant colorectal cancer
Roswell Park Cancer Institute Corp
FY2025$542,949R37CA282430 - Novel synthetic lethality strategy for TP53 mutant colorectal cancer
Roswell Park Cancer Institute Corp
FY2024$502,520R37CA282430
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip McCarthy, MD
Roswell Park Comprehensive Cancer Center
Saby George, MD
Roswell Park Comprehensive Cancer Center
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center
Shashikant Lele, MD
Roswell Park Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”